Prime Medicine Announces Proposed Public Offering of Common Stock
February 14, 2024 16:05 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Receives Up to $15 Million from Cystic Fibrosis Foundation to Advance Hotspot and PASSIGE™ Prime Editors for Cystic Fibrosis
January 25, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
January 05, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 08:00 ET
|
Prime Medicine, Inc.
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic...
Prime Medicine to Present at Upcoming Investor Conferences
November 08, 2023 08:00 ET
|
Prime Medicine, Inc.
Cambridge, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic...
Prime Medicine Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 03, 2023 16:01 ET
|
Prime Medicine, Inc.
-- Presented new preclinical research across multiple programs, including proof-of-concept data from in vivo rodent and large animal studies, as well as updates on proprietary delivery systems -- ...
Prime Medicine Presents First-ever Prime Editing Data in Non-human Primates Demonstrating Highly Efficient Ability of Prime Editors to Precisely Correct Disease-causing Mutation of GSD1b
October 27, 2023 06:00 ET
|
Prime Medicine, Inc.
Up to 83% of Hepatocytes (up to 50% whole liver) Precisely Edited for p.L358fs Mutation Following IV Infusion of Prime Editor in NHPs with No Safety Concerns Observed; Editing Well Above Anticipated...
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
October 24, 2023 07:30 ET
|
Prime Medicine, Inc.
Prime Medicine Presents First In Vivo Proof-of-Concept Prime Editing Data Demonstrating Ability of Prime Editors to Treat Ophthalmological Diseases
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences
October 17, 2023 08:00 ET
|
Prime Medicine, Inc.
Prime Medicine to Highlight Positive Preclinical Developments Across Prime Editing Pipeline and Platform at Upcoming Industry Conferences